WO1995022335A1 - Acidified nitrite as an antimicrobial agent - Google Patents

Acidified nitrite as an antimicrobial agent Download PDF

Info

Publication number
WO1995022335A1
WO1995022335A1 PCT/GB1995/000338 GB9500338W WO9522335A1 WO 1995022335 A1 WO1995022335 A1 WO 1995022335A1 GB 9500338 W GB9500338 W GB 9500338W WO 9522335 A1 WO9522335 A1 WO 9522335A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acidifying agent
nitrate
nitrite
dosage form
Prior art date
Application number
PCT/GB1995/000338
Other languages
French (fr)
Inventor
Nigel Benjamin
Hamish Dougall
Original Assignee
Aberdeen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9403284A external-priority patent/GB9403284D0/en
Priority claimed from GB9404365A external-priority patent/GB9404365D0/en
Priority to MX9603535A priority Critical patent/MX9603535A/en
Priority to EP95908347A priority patent/EP0746327B1/en
Priority to DE69532921T priority patent/DE69532921T2/en
Priority to AT95908347T priority patent/ATE264685T1/en
Priority to DK95908347T priority patent/DK0746327T3/en
Priority to JP52166995A priority patent/JP3875262B2/en
Application filed by Aberdeen University filed Critical Aberdeen University
Priority to PL95316033A priority patent/PL180769B1/en
Priority to AU16699/95A priority patent/AU693851B2/en
Priority to BR9507099A priority patent/BR9507099A/en
Priority to CA002183549A priority patent/CA2183549C/en
Publication of WO1995022335A1 publication Critical patent/WO1995022335A1/en
Priority to FI963232A priority patent/FI114852B/en
Priority to NO19963446A priority patent/NO311494B1/en
Priority to US09/330,654 priority patent/US6709681B2/en
Priority to US10/701,295 priority patent/US20040105898A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Definitions

  • the present invention relates to acidified nitrite as an antimicrobial agent.
  • nitrite has been used as a preservative for food for many years the mechanisms by which it kills microorganisms has not been elucidated. We have now found that nitrite in low concentration is effective in reducing the populations of bacteria, fungi and viruses on the animal body when pH is below 4. We believe that this mechanism is used by mammals to destroy swallowed microorganisms.
  • An active entero-salivary circulation in man provides a continuous flow of nitrate into the mouth where it is rapidly reduced to nitrite by bacteria on the tongue.
  • the effect of salivary nitrate excretion is to provide a precursor for the generation of nitrogen oxides by the break down of the nitrite.
  • nitrates In the mouth bacteria rapidly reduce nitrates to nitrites. Once swallowed the acid conditions of the stomach protonate the nitrite to form nitrous acid (pKa approx 3.5) . The nitrous acid in turn dissociates to form oxides of nitrogen as shown below.
  • Endogenous and dietary nitrate is actively concentrated by salivary glands to more than 10 times the concentration in plasma and secreted in saliva.
  • saliva provides a continuous source of nitrate to the upper gastrointestinal tract.
  • Oral conversion of nitrate to nitrite is rapid and is restricted to the surface of the tongue in man and to the posterior third of the tongue in the rat.
  • entero-salivary circulation of nitrate The function of the entero-salivary circulation of nitrate is not known but it may well be that gastric acid by itself is not always sufficient to destroy many ingested micro-organisms and that the primary role of salivary nitrate secretion and conversion to nitrite is as a precursor for nitrogen oxides in the lumen of the stomach which will kill swallowed micro ⁇ organisms.
  • the above identified mechanism is also applicable to the destruction of micro-organisms on the skin. For example athlete's foot or tidea pedis.
  • nitrite at concentrations of up to 4% in an inert carrier cream or ointment when mixed with an organic acid such as salicylic acid reacts to produce oxides of nitrogen which are effective in killing infectious organisms on the skin including fungi, yeast, bacteria and viruses.
  • organic acid such as salicylic acid
  • the above identified mechanism is also useful in the sterilisation of objects such as dentures by utilising a sterilizing nitrate solution.
  • Conventional solutions which are effective in sterilising dentures often taste unpleasant due to chlorine-based disinfectants.
  • a combination of nitrite and aci ⁇ - results in a antimicrobial solution which has little or no taste.
  • Other objects such as contact lenses may be sterilised in the same way.
  • Gastroenteritis continues to be a major problem in rearing pigs and other farm animals. Enteropathogenic Escherichia coli (especially those bearing the K88 antigen) are particularly implicated. Although gastric acidity is thought to be one of the main host defence systems which provides a barrier to orally-acquired infection, this is clearly ineffective in preventing organisms from reaching the more distal intestine in these animals.
  • a dosage form for the treatment of bacterial, virus, or fungal conditions which comprises:- a pharmaceutically acceptable acidifying agent, a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor, and a pharmaceutically acceptable carrier or diluent, wherein the acidifying agent is adapted to reduce the pH at the environment of use to below pH4.
  • the acidifying agent is an organic acid, for example salicylic acid or ascorbic acid.
  • the precursor for the nitrite ion may be an alkaline metal or alkaline earth metal nitrate capable of conversion to a nitrate by enzymic action.
  • the pharmaceutical acceptable carrier or diluent may be an inert cream or ointment.
  • the acidifying agent and the source of nitrite ions or precursor therefor are separately disposed in said cream or ointment for admixture to release nitrite ions at the environment of use.
  • an acid composition may be presented for administration in tablet or liquid form.
  • a method of sterilising an object which method comprises the steps of
  • a sterilant composition comprising a pharmaceutically acceptable acidifying agent, a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor, and a pharmaceutically acceptable carrier or diluent therefor wherein the acidifying agent is adapted to reduce the pH at the environment of use to below pH4.
  • an animal feed supplement comprising a pharmaceutically acceptable acidifying agent and, a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor, in an amount sufficient to produce a beneficial anti-bacterial pharmalogical effect, but insufficient to produce adverse action in the target animal.
  • the acidifying agent may be salicylic or ascorbic acid as above, and the source of nitrite ions or nitrate precursor therefor may be in an inorganic nitrate as set forth above.
  • the supplement should be included in an amount sufficient to ensure that each adult animal will receive a balanced dose of between 0.3 to 5.0 g/day and preferably about 1 g/day.
  • Figure 1 shows a diagram indicative of the effect of exposure to nitrate and differing hydrogen ion concentrations on the survival of C albicans where the vertical axis is the optical density in absorbance units and the horizontal axis is the pH.
  • Figure 2 shows growth curves of E coli following exposure to acid alone or acid with a nitrite where the vertical axes are optical density in absorbance units and the horizontal axes are time in hours.
  • Figure 3 shows growth curves of E coli following exposure to pH3 in various nitrite concentrations where the vertical axis shows the optical density in absorbance units and the horizontal axis is time in hours.
  • Figure 4 shows the generation of nitric oxide from sodium nitrite at different levels of acidity where the vertical axis is the nitric oxide concentration (nM) and the horizontal axis is Ph.
  • EXAMPLE 1 With reference to Figure 1 a single colony of C albicans was used to inoculate an overnight culture in Sabouraud's broth. 10nl of this broth was added to 940 ⁇ l of a citrate/phosphate buffered Sabouraud's broth to which was added sodium nitrite (50 ⁇ l; final concentration 250 ⁇ M) or distilled water as a control. After one hour incubation at 37°C, lO ⁇ l was removed and cultured in 190 ⁇ l standard Sabourauds broth with continual agitation (Gallenkamp orbital incubator) in a 96-well microtitre plate at 37°C. Growth was monitored by measurement of optical density at 570nm at regular time intervals. The results are a mean of 16 separate experiments.
  • the nitrite was in fact effective in eliminating C albicans at pH 1 at all concentrations above 250 ⁇ M (data not shown) .
  • 5nN nitrite killed C albicans at up to pH5. It is significant that a random sample of 10 laboratory personnel on a normal diet had fasting salivary nitrite which varied from 23 to 220 ⁇ M (mean 114 ⁇ M) rising to 409 to 1890 ⁇ M (mean 1030) 45 minutes after ingestion of 200mg potassium nitrate solution.
  • Figure 2 shows growth curves of E coli following exposure to acid alone (open symbols) or acid and 250 ⁇ M nitrite (closed symbols) . Growth was significantly (p ⁇ 0.05) impaired at pH 2,3 and 4 in the presence of nitrite compared with control.
  • E coli strain NCTC 10418 grown on MacConkey's agar
  • nutrient both Oxoid CM1
  • the results shown in Figure 2 are a mean of 20 experiments.
  • E coli is more susceptible to acid than C albicans. Nevertheless exposure to pH 2 for one hour does not kill all the organisms as there is significant growth in the nutrient broth. At pH3 many organisms survive.
  • the addition of 250 ⁇ M nitrite to the exposure medium eliminates E coli at pH2 and significantly reduces the viability of this organism at pH3 and pH4. Nitrite at this concentration had no effect above pH4.
  • Figure 3 shows growth curves of E coli following exposure to pH3 in various nitrite concentrations (10-1000 ⁇ M final concentration) . The methods are those as for Figure 2.
  • Figure 3 shows that there is a direct relationship between the toxic effects of nitrite on E coli and nitrate concentration at pH3. Even lO ⁇ M had a discernable effect whereas ImM killed E coli completely.
  • Figure 4 shows the generation of nitric oxide from sodium nitrite (as ⁇ M) at different acidities. Conditions were the same as those used for the exposure of organisms in Figure 1. In particular nitrite was added to citrate/phosphate buffer to achieve final concentrations shown in Figure 4. Nitric oxide concentrations in the buffer were measured by a nitric oxide sensitive meter (ISO-NO, World Precision Instruments) connected to a Maclab acquisition system and Macintosh computer. Measurements were recorded continually and readings were taken at 2 minutes when nitric oxide concentration had reached a steady state. Figure 4 shows the release of nitric oxide as a result of reducing pH.
  • ISO-NO World Precision Instruments
  • Nitric oxide which we have shown is generated under experimental conditions in Figure 4 readily diffuses through cell membranes and has a high affinity for iron-sulphur containing respiratory enzymes and damages bacterial DNA.
  • nitric acid When produced enzymatically by activated leucocytes, nitric acid will kill Leishmania sp.. Staphylococcus sp. , Francisella sp. and Microbacterium as well as C albicans. Reaction with superoxide under acid conditions may additionally produce highly reactive hydroxyl radicals.
  • the symptom score (derived from a scoring system which measures erythema, vesicles, pustules, desquamation, encrustation and pruritus) decreased from a mean of 7 before treatment to a mean of 2 following treatment.
  • E coli is closely related to Salmonella, Shiqella and other pathogenic enterobacteria; all important causes of gastroenteritis in the mammal.
  • Nitrate itself is a innocuous precursor which only produces microbiocidal species when converted to nitrite and subjected to acid conditions. It is possible that Lactobacilli sp. transiently produce sufficient acid in the mouth after a carbohydrate meal to control the growth of oral pathogens but clearly a moderate intake of nitrate may be a desirable prerequisite in any contaminated environment despite any potential as a precursor of nitrosamines.
  • intestinal nitrogen oxides may be inadequate if the oral flora which convert nitrate to nitrite are suppressed following therapy with broad-spectrum antibiotics. Similarly if gastric acid production is reduced, or if nitrate intake, which is largely dependent on leafy vegetables, is low this protective mechanism will be impaired. These are precisely the situations which predispose to oral and intestinal infections.
  • the invention provides a dosage form for the treatment of bacterial, viral or fungal conditions, a method of sterilising an object, and a composition therefor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to the use of acidified nitrite as an antimicrobial agent and describes a dosage form for use in the treatment of bacterial, viral or fungal conditions. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. Amongst the many potential applications for the invention, the inventive composition has been shown to be particularly effective as an animal feed supplement, and as an agent for sterilising objects. Compositions and methods of use for these applications are described.

Description

ACIDIFIED NITRITE AS AN ANTIMICROBIAL AGENT
The present invention relates to acidified nitrite as an antimicrobial agent.
Although nitrite has been used as a preservative for food for many years the mechanisms by which it kills microorganisms has not been elucidated. We have now found that nitrite in low concentration is effective in reducing the populations of bacteria, fungi and viruses on the animal body when pH is below 4. We believe that this mechanism is used by mammals to destroy swallowed microorganisms.
An active entero-salivary circulation in man provides a continuous flow of nitrate into the mouth where it is rapidly reduced to nitrite by bacteria on the tongue. The effect of salivary nitrate excretion is to provide a precursor for the generation of nitrogen oxides by the break down of the nitrite.
In brief we have found that exposure of a yeast, Candida albicans and the bacterium E coli to concentrations of nitrite in saliva together with acid conditions similar to those found in the stomach for one hour caused a dose-dependent reduction in their survival. It is apparent therefore that the generation of nitrogen oxides and/or nitrous acid in the mouth and in the gastrointestinal tract, particularly the upper gastrointestinal tract, from acidified nitrite is preventative of icrobial infection.
In the mouth bacteria rapidly reduce nitrates to nitrites. Once swallowed the acid conditions of the stomach protonate the nitrite to form nitrous acid (pKa approx 3.5) . The nitrous acid in turn dissociates to form oxides of nitrogen as shown below.
N02 - + H+ = HN02 (1) 2HN02 = H20 + N-.O3 (2)
N203 = NO + N02 (3)
Endogenous and dietary nitrate is actively concentrated by salivary glands to more than 10 times the concentration in plasma and secreted in saliva. Thus the saliva provides a continuous source of nitrate to the upper gastrointestinal tract. Oral conversion of nitrate to nitrite is rapid and is restricted to the surface of the tongue in man and to the posterior third of the tongue in the rat.
The function of the entero-salivary circulation of nitrate is not known but it may well be that gastric acid by itself is not always sufficient to destroy many ingested micro-organisms and that the primary role of salivary nitrate secretion and conversion to nitrite is as a precursor for nitrogen oxides in the lumen of the stomach which will kill swallowed micro¬ organisms.
The above identified mechanism is also applicable to the destruction of micro-organisms on the skin. For example athlete's foot or tidea pedis.
We have found that nitrite at concentrations of up to 4% in an inert carrier cream or ointment when mixed with an organic acid such as salicylic acid reacts to produce oxides of nitrogen which are effective in killing infectious organisms on the skin including fungi, yeast, bacteria and viruses. The combination of nitrite and acid causes mild erythema (redness) of the skin due to release of nitric oxides but this causes no significant inflammation.
The above identified mechanism is also useful in the sterilisation of objects such as dentures by utilising a sterilizing nitrate solution. Conventional solutions which are effective in sterilising dentures often taste unpleasant due to chlorine-based disinfectants. A combination of nitrite and aci<- results in a antimicrobial solution which has little or no taste. Other objects such as contact lenses may be sterilised in the same way.
Gastroenteritis continues to be a major problem in rearing pigs and other farm animals. Enteropathogenic Escherichia coli (especially those bearing the K88 antigen) are particularly implicated. Although gastric acidity is thought to be one of the main host defence systems which provides a barrier to orally-acquired infection, this is clearly ineffective in preventing organisms from reaching the more distal intestine in these animals.
According therefore to a first aspect of the present invention there is provided a dosage form for the treatment of bacterial, virus, or fungal conditions which comprises:- a pharmaceutically acceptable acidifying agent, a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor, and a pharmaceutically acceptable carrier or diluent, wherein the acidifying agent is adapted to reduce the pH at the environment of use to below pH4. Preferably the acidifying agent is an organic acid, for example salicylic acid or ascorbic acid. The precursor for the nitrite ion may be an alkaline metal or alkaline earth metal nitrate capable of conversion to a nitrate by enzymic action.
The pharmaceutical acceptable carrier or diluent may be an inert cream or ointment. In a particularly preferred form of the invention the acidifying agent and the source of nitrite ions or precursor therefor are separately disposed in said cream or ointment for admixture to release nitrite ions at the environment of use.
Alternatively an acid composition may be presented for administration in tablet or liquid form. In a further aspect of the invention there is provided a method of sterilising an object which method comprises the steps of
1) preparing a pharmaceutically acceptable acidifying agent and a pharmaceutically acceptable source of nitrite ions,
2) mixing said acidifying agent with said source of nitrite ions in a liquid carrier or diluent in contact with said object thereby to reduce the pH to below 4 while causing said sterilant nitrite ions to sterilize said object.
In a further form of the invention there is provided a sterilant composition comprising a pharmaceutically acceptable acidifying agent, a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor, and a pharmaceutically acceptable carrier or diluent therefor wherein the acidifying agent is adapted to reduce the pH at the environment of use to below pH4.
In a still further form of the invention there is provided an animal feed supplement comprising a pharmaceutically acceptable acidifying agent and, a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor, in an amount sufficient to produce a beneficial anti-bacterial pharmalogical effect, but insufficient to produce adverse action in the target animal.
The acidifying agent may be salicylic or ascorbic acid as above, and the source of nitrite ions or nitrate precursor therefor may be in an inorganic nitrate as set forth above. Where the animal is the pig, the supplement should be included in an amount sufficient to ensure that each adult animal will receive a balanced dose of between 0.3 to 5.0 g/day and preferably about 1 g/day.
The invention will now be described, by way of illustration only, with reference to the following examples and figures accompanying the specification.
Figure 1 shows a diagram indicative of the effect of exposure to nitrate and differing hydrogen ion concentrations on the survival of C albicans where the vertical axis is the optical density in absorbance units and the horizontal axis is the pH.
Figure 2 shows growth curves of E coli following exposure to acid alone or acid with a nitrite where the vertical axes are optical density in absorbance units and the horizontal axes are time in hours.
Figure 3 shows growth curves of E coli following exposure to pH3 in various nitrite concentrations where the vertical axis shows the optical density in absorbance units and the horizontal axis is time in hours.
Figure 4 shows the generation of nitric oxide from sodium nitrite at different levels of acidity where the vertical axis is the nitric oxide concentration (nM) and the horizontal axis is Ph.
EXAMPLE 1 With reference to Figure 1 a single colony of C albicans was used to inoculate an overnight culture in Sabouraud's broth. 10nl of this broth was added to 940μl of a citrate/phosphate buffered Sabouraud's broth to which was added sodium nitrite (50μl; final concentration 250μM) or distilled water as a control. After one hour incubation at 37°C, lOμl was removed and cultured in 190μl standard Sabourauds broth with continual agitation (Gallenkamp orbital incubator) in a 96-well microtitre plate at 37°C. Growth was monitored by measurement of optical density at 570nm at regular time intervals. The results are a mean of 16 separate experiments.
The effect of exposure to nitrite and differing hydrogen ion concentrations on the survival of C albicans is shown in Figure 1. The open bars show the growth of C albicans measured by the optical density method following exposure to acid alone for 1 hour, while the closed bars show growth following exposure to acid and 250μM sodium nitrite. There is a significant difference from the control at p>0.05 (Mann- Whitney U test) . It is apparent therefore that the incubation of C albicans in acid alone for one hour had little effect on the number of viable organisms subsequently grown, whereas in contrast the addition of sodium nitrite at 250μM incrementally killed C albicans as the pH was reduced to below 4. The nitrite was in fact effective in eliminating C albicans at pH 1 at all concentrations above 250μM (data not shown) . 5nN nitrite killed C albicans at up to pH5. It is significant that a random sample of 10 laboratory personnel on a normal diet had fasting salivary nitrite which varied from 23 to 220μM (mean 114μM) rising to 409 to 1890μM (mean 1030) 45 minutes after ingestion of 200mg potassium nitrate solution.
EXAMPLE 2
Figure 2 shows growth curves of E coli following exposure to acid alone (open symbols) or acid and 250μM nitrite (closed symbols) . Growth was significantly (p^0.05) impaired at pH 2,3 and 4 in the presence of nitrite compared with control.
The same methods were used as in Figure 1 except E coli (strain NCTC 10418 grown on MacConkey's agar) was used and nutrient both (Oxoid CM1) was used in place of Sabouraud's broth. The results shown in Figure 2 are a mean of 20 experiments. As can be seen from Figure 2 E coli is more susceptible to acid than C albicans. Nevertheless exposure to pH 2 for one hour does not kill all the organisms as there is significant growth in the nutrient broth. At pH3 many organisms survive. The addition of 250μM nitrite to the exposure medium eliminates E coli at pH2 and significantly reduces the viability of this organism at pH3 and pH4. Nitrite at this concentration had no effect above pH4. EXAMPLE 3
Figure 3 shows growth curves of E coli following exposure to pH3 in various nitrite concentrations (10-1000μM final concentration) . The methods are those as for Figure 2. Figure 3 shows that there is a direct relationship between the toxic effects of nitrite on E coli and nitrate concentration at pH3. Even lOμM had a discernable effect whereas ImM killed E coli completely.
EXAMPLE 4
Figure 4 shows the generation of nitric oxide from sodium nitrite (as μM) at different acidities. Conditions were the same as those used for the exposure of organisms in Figure 1. In particular nitrite was added to citrate/phosphate buffer to achieve final concentrations shown in Figure 4. Nitric oxide concentrations in the buffer were measured by a nitric oxide sensitive meter (ISO-NO, World Precision Instruments) connected to a Maclab acquisition system and Macintosh computer. Measurements were recorded continually and readings were taken at 2 minutes when nitric oxide concentration had reached a steady state. Figure 4 shows the release of nitric oxide as a result of reducing pH. Nitric oxide, which we have shown is generated under experimental conditions in Figure 4 readily diffuses through cell membranes and has a high affinity for iron-sulphur containing respiratory enzymes and damages bacterial DNA. When produced enzymatically by activated leucocytes, nitric acid will kill Leishmania sp.. Staphylococcus sp. , Francisella sp. and Microbacterium as well as C albicans. Reaction with superoxide under acid conditions may additionally produce highly reactive hydroxyl radicals.
EXAMPLE 5
In a study to investigate the effect of a combination of salicylic acid at 2% w/w and sodium nitrite at 2% w/w in 9 patient volunteers with microbiologically proven fungal infection of the feet, application of the treatment produced a microbiological cure in all but one patient after 2 weeks of therapy. The symptom score (derived from a scoring system which measures erythema, vesicles, pustules, desquamation, encrustation and pruritus) decreased from a mean of 7 before treatment to a mean of 2 following treatment.
EXAMPLE 6
Investigation of the use of nitrate or nitrite administered topically in the mouth in the form of toothpaste, mouthwash or other orally acceptable vehicle to reduce the number of caries-producing organisms in dental plaque and to treat to prevent infection with C albicans or other harmful organisms showed such application to be effective.
The observation that oxides of nitrogen produced non- enzymatically from nitrite under conditions simulating those in the stomach kills C albicans and E coli extends these observations to the intestinal tract. E coli is closely related to Salmonella, Shiqella and other pathogenic enterobacteria; all important causes of gastroenteritis in the mammal.
These results provide a rationale for active secretion of nitrate by the salivary glands. Nitrate itself is a innocuous precursor which only produces microbiocidal species when converted to nitrite and subjected to acid conditions. It is possible that Lactobacilli sp. transiently produce sufficient acid in the mouth after a carbohydrate meal to control the growth of oral pathogens but clearly a moderate intake of nitrate may be a desirable prerequisite in any contaminated environment despite any potential as a precursor of nitrosamines.
Further the production of intestinal nitrogen oxides may be inadequate if the oral flora which convert nitrate to nitrite are suppressed following therapy with broad-spectrum antibiotics. Similarly if gastric acid production is reduced, or if nitrate intake, which is largely dependent on leafy vegetables, is low this protective mechanism will be impaired. These are precisely the situations which predispose to oral and intestinal infections.
Whereas the foregoing study has concentrated on C albicans and E coli and the other organisms mentioned, it may also be important for providing protection from other serious gut pathogens which when swallowed may cause duodenal ulceration, for example Helicobacter pylori, amoebic dysentery and chronic intestinal parasitism. Accordingly the invention provides a dosage form for the treatment of bacterial, viral or fungal conditions, a method of sterilising an object, and a composition therefor.
The above also suggests an inexpensive and simple means of prevention of gastroenteritis in farmed pigs by modification of dietary nitrate intake without the use of antibiotics.

Claims

1. A dosage form for treatment of bacterial, viral or fungal conditions which comprises; a pharmaceutically acceptable acidifying agent, a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor, and a pharmaceutically acceptable carrier or diluent therefor, wherein the acidifying agent is present in an amount sufficient to reduce the pH at the environment of use to below pH4.
2. A dosage form according to claim 1 wherein the acidifying agent is an organic acid.
3. A dosage form according to claim 2 wherein the acidifying agent is salicylic or ascorbic acid.
4. A dosage form according to any preceding claim wherein the nitrate precursor is an alkali metal or alkali earth metal nitrate.
5. A dosage form according to any preceding claim wherein the pharmaceutically acceptable carrier is disposed in an inert cream or ointment, and wherein said acidifying agent and said source of nitrite ions is separately disposed in a respective cream or ointment for admixture to release nitrate ions at the intended environment of use.
6. A dosage form according to any of claims 1 to 4 in tablet or liquid form.
7. A method of sterilising an object which method comprises the steps of:- 1) preparing a pharmaceutically acceptable acidifying agent and a pharmaceutically acceptable source of nitrate ions or a nitrate precursor therefor, 2) admixing said acidifying agent with said source of nitrite ions in a liquid carrier or diluent in contact with said object, thereby to reduce the pH to below 4 to release sterilant nitrite ions to sterilize said object.
8. A method according to claim 7 wherein said acidifying agent is an organic acid.
9. A method according to claim 8 wherein said organic acid is a salicylic acid.
10. A method according to any of claims 7 to 9 wherein said precursor is an alkali metal or alkali earth metal nitrate.
11. A sterilant composition comprising a pharmaceutically acceptable acidifying agent, a pharmaceutically acceptable form of nitrite ions or a precursor therefor, and a pharmaceutically acceptable carrier or diluent therefor, wherein the acidifying agent is adapted to reduce the pH at the environment of use to below 4.
12. An animal feed supplement comprising a pharmaceutically acceptable acidifying agent, and a pharmaceutically acceptable source of nitrite ions or a nitrate precursor therefor, in an amount sufficient to produce a beneficial anti-bacterial effect but insufficient to produce an adverse reaction in a target animal.
13. An animal feed supplement according to claim 12 wherein the acidifying agent is selected from salicylic or ascorbic acid.
14. An animal feed supplement according to either of claims 12 or 13 wherein the source of nitrite ions is an inorganic nitrate.
15. An animal feed supplement according to claim 14 wherein the feed supplement is adapted for the pig, and the inorganic nitrate is present in the feed in an amount sufficient to provide an adult pig with about 1 g/day.
PCT/GB1995/000338 1994-02-21 1995-02-17 Acidified nitrite as an antimicrobial agent WO1995022335A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
BR9507099A BR9507099A (en) 1994-02-21 1995-02-17 Dosage form sterilization method sterilizing composition and animal food supplement comprising acidified nitrite as an anti-microbial agent
CA002183549A CA2183549C (en) 1994-02-21 1995-02-17 Acidified nitrite as an antimicrobial agent
PL95316033A PL180769B1 (en) 1994-02-21 1995-02-17 Acidified nitrite as an agent against micro-organisms
DE69532921T DE69532921T2 (en) 1994-02-21 1995-02-17 Deacidified Nitrite for use as an antimicrobial agent
AT95908347T ATE264685T1 (en) 1994-02-21 1995-02-17 ACIDIFIED NITRITE FOR USE AS AN ANTIMICROBIAL AGENT
DK95908347T DK0746327T3 (en) 1994-02-21 1995-02-17 Acidified nitrite as an antimicrobial agent
JP52166995A JP3875262B2 (en) 1994-02-21 1995-02-17 Acidified nitrite as a disinfectant
MX9603535A MX9603535A (en) 1994-03-07 1995-02-17 Acidified nitrite as an antimicrobial agent.
EP95908347A EP0746327B1 (en) 1994-02-21 1995-02-17 Acidified nitrite as an antimicrobial agent
AU16699/95A AU693851B2 (en) 1994-02-21 1995-02-17 Acidified nitrite as an antimicrobial agent
FI963232A FI114852B (en) 1994-02-21 1996-08-16 Acidified nitrate for use as an antimicrobial agent
NO19963446A NO311494B1 (en) 1994-02-21 1996-08-19 Dosage form for treatment of microbiological conditions in humans or animals, method of sterilization of disposable articles, sterilizing mixture, as well as animal feed supplements
US09/330,654 US6709681B2 (en) 1995-02-17 1999-06-11 Acidified nitrite as an antimicrobial agent
US10/701,295 US20040105898A1 (en) 1994-02-21 2003-11-03 Acidified nitrite as an antimicrobial agent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9403284.4 1994-02-21
GB9403284A GB9403284D0 (en) 1994-02-21 1994-02-21 Acidified nitrite as antimicrobial agent
GB9404365.0 1994-03-07
GB9404365A GB9404365D0 (en) 1994-03-07 1994-03-07 Acidified nitrate as antimicrobial agent

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB1999/000605 Continuation-In-Part WO1999044622A1 (en) 1994-02-21 1999-03-01 Inorganic nitrite and organic acid in combination as topical antiviral composition
US09/330,654 Continuation US6709681B2 (en) 1994-02-21 1999-06-11 Acidified nitrite as an antimicrobial agent

Publications (1)

Publication Number Publication Date
WO1995022335A1 true WO1995022335A1 (en) 1995-08-24

Family

ID=26304368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/000338 WO1995022335A1 (en) 1994-02-21 1995-02-17 Acidified nitrite as an antimicrobial agent

Country Status (17)

Country Link
EP (1) EP0746327B1 (en)
JP (1) JP3875262B2 (en)
KR (1) KR100385297B1 (en)
CN (1) CN1145491C (en)
AT (1) ATE264685T1 (en)
AU (1) AU693851B2 (en)
BR (1) BR9507099A (en)
CA (1) CA2183549C (en)
CZ (1) CZ286286B6 (en)
DE (1) DE69532921T2 (en)
DK (1) DK0746327T3 (en)
ES (1) ES2218541T3 (en)
FI (1) FI114852B (en)
NO (1) NO311494B1 (en)
PL (1) PL180769B1 (en)
PT (1) PT746327E (en)
WO (1) WO1995022335A1 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047495A1 (en) * 1997-02-21 1998-10-29 Nitricare Kb New composition
WO1999044622A1 (en) * 1998-03-02 1999-09-10 Aberdeen University Inorganic nitrite and organic acid in combination as topical antiviral composition
WO2000053193A1 (en) * 1999-03-09 2000-09-14 Queen Mary & Westfield College Pharmaceutical composition containing nitrate source and an acidifying agent for treating skin ischaemia
WO2002017881A2 (en) * 2000-08-30 2002-03-07 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
WO2002020026A2 (en) * 2000-09-08 2002-03-14 Aberdeen University Treatment of drug resistant organisms with nitric oxide
WO2003018102A2 (en) 2001-08-29 2003-03-06 Vectura Limited Topical administration device
WO2003032928A2 (en) * 2001-10-19 2003-04-24 Barts And The London Nhs Trust Therapeutic composition and use
US6682732B1 (en) 1998-08-28 2004-01-27 The University Of Bath Treatment of lesions
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
GB2435613A (en) * 2006-03-03 2007-09-05 Optinose As Sustained release composition for the nasal mucosa comprising nitric oxide, and a device for delivering it to the nasal mucosa
US20090317492A1 (en) * 2006-04-12 2009-12-24 Robert Allaker Therapeutic Composition and Use
US20100129474A1 (en) * 2006-09-22 2010-05-27 University Of Exeter Agricultural treatment
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8557300B2 (en) 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US8927030B2 (en) 2003-07-09 2015-01-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same
US9381381B2 (en) 2001-08-03 2016-07-05 Aberdeen University Treatment of nail infections with no
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2020245574A1 (en) 2019-06-04 2020-12-10 Thirty Respiratory Limited Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
WO2020245573A1 (en) 2019-06-04 2020-12-10 Thirty Holdings Limited Methods and compositions for generating nitric oxide and uses thereof
WO2021214440A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2
WO2021214439A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Methods and compositions for treating and combatting tuberculosis
WO2022167797A1 (en) 2021-02-04 2022-08-11 Thirty Respiratory Limited Vaping e-liquid composition and use thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432077B1 (en) * 2000-12-26 2002-08-13 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
PT1861130E (en) * 2005-02-11 2008-12-02 Nolabs Ab Device and method for treatment of dermatomycosis, and in particular onychomycosis
US20160193336A1 (en) * 2013-10-31 2016-07-07 Origin, Inc. Methods for using nitric oxide in a plasma state to treat medical conditions and diseases
EP3427760A1 (en) * 2014-06-13 2019-01-16 Origin, Inc. A method for disinfecting clothes, shoes or equipment using nitric oxide
BR112017011870B1 (en) * 2014-12-05 2022-09-20 Can Technologies, Inc PREMIXTURE, SUPPLEMENT FOR AN ANIMAL FOOD AND METHOD FOR FEEDING AN ANIMAL
KR20200027951A (en) 2017-06-23 2020-03-13 캔 테크놀로지스 인코포레이티드 How to improve meat quality

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191750A (en) * 1976-03-08 1980-03-04 Milton Hodosh Method for treating canker sores
JPS5985278A (en) * 1982-11-05 1984-05-17 Agency Of Ind Science & Technol Preservation of food and preserving material
JPS62142559A (en) * 1985-12-18 1987-06-25 株式会社祥光化学研究所 Structure having deodorizing and antibacterial functions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191750A (en) * 1976-03-08 1980-03-04 Milton Hodosh Method for treating canker sores
JPS5985278A (en) * 1982-11-05 1984-05-17 Agency Of Ind Science & Technol Preservation of food and preserving material
JPS62142559A (en) * 1985-12-18 1987-06-25 株式会社祥光化学研究所 Structure having deodorizing and antibacterial functions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 2684, Derwent World Patents Index; AN 84-161228 *
DATABASE WPI Week 3187, Derwent World Patents Index; AN 87-217091 *

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
WO1998047495A1 (en) * 1997-02-21 1998-10-29 Nitricare Kb New composition
AU758264B2 (en) * 1998-03-02 2003-03-20 Aberdeen University Inorganic nitrite and organic acid in combination as topical antiviral composition
WO1999044622A1 (en) * 1998-03-02 1999-09-10 Aberdeen University Inorganic nitrite and organic acid in combination as topical antiviral composition
US6682732B1 (en) 1998-08-28 2004-01-27 The University Of Bath Treatment of lesions
WO2000053193A1 (en) * 1999-03-09 2000-09-14 Queen Mary & Westfield College Pharmaceutical composition containing nitrate source and an acidifying agent for treating skin ischaemia
JP2002538210A (en) * 1999-03-09 2002-11-12 クイーン メアリー アンド ウェストフィールド カレッジ Pharmaceutical composition comprising a nitrate source and an acidifying agent for treating cutaneous ischemia
WO2002017881A2 (en) * 2000-08-30 2002-03-07 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
WO2002017881A3 (en) * 2000-08-30 2003-04-17 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
US8128964B2 (en) 2000-08-30 2012-03-06 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
US8114442B2 (en) 2000-08-30 2012-02-14 Queen Mary & Westfield College Transdermal pharmaceutical delivery compositions
WO2002020026A3 (en) * 2000-09-08 2002-05-16 Univ Aberdeen Treatment of drug resistant organisms with nitric oxide
WO2002020026A2 (en) * 2000-09-08 2002-03-14 Aberdeen University Treatment of drug resistant organisms with nitric oxide
US9381381B2 (en) 2001-08-03 2016-07-05 Aberdeen University Treatment of nail infections with no
WO2003018102A2 (en) 2001-08-29 2003-03-06 Vectura Limited Topical administration device
WO2003032928A2 (en) * 2001-10-19 2003-04-24 Barts And The London Nhs Trust Therapeutic composition and use
AU2002334190B2 (en) * 2001-10-19 2008-12-11 Barts And The London Nhs Trust Therapeutic composition and use
JP2005508957A (en) * 2001-10-19 2005-04-07 バーツ アンド ザ ロンドン エヌエイチエス トラスト Therapeutic compositions and uses
WO2003032928A3 (en) * 2001-10-19 2003-09-18 Barts & London Nhs Trust Therapeutic composition and use
US9675637B2 (en) 2003-07-09 2017-06-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US9387224B2 (en) 2003-07-09 2016-07-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment of specific cardiovascular conditions with nitrite
US9700578B2 (en) 2003-07-09 2017-07-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US8927030B2 (en) 2003-07-09 2015-01-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US8557300B2 (en) 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9403851B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US11691995B2 (en) 2005-05-27 2023-07-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9403852B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8956658B2 (en) 2005-05-27 2015-02-17 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8962029B2 (en) 2005-05-27 2015-02-24 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
GB2454044B (en) * 2006-03-03 2010-12-08 Optinose As Sustained release formulation for release of nitric oxide to nasal mucosa
GB2454044A (en) * 2006-03-03 2009-04-29 Optinose As Sustained release composition to the nasal mucosa comprising nitric oxide, and a device therefore
GB2435613B (en) * 2006-03-03 2011-03-02 Optinose As Combination of sustained release formulation and nasal delivery device for sustained release of nitric oxide to nasal mucosa
GB2435613A (en) * 2006-03-03 2007-09-05 Optinose As Sustained release composition for the nasal mucosa comprising nitric oxide, and a device for delivering it to the nasal mucosa
US9011935B2 (en) 2006-04-12 2015-04-21 Barts Health National Health Service Trust Therapeutic composition and use
US20150140131A1 (en) * 2006-04-12 2015-05-21 Barts And The London Nhs Trust Fund Therapeutic Composition And Use
US20090317492A1 (en) * 2006-04-12 2009-12-24 Robert Allaker Therapeutic Composition and Use
US20100129474A1 (en) * 2006-09-22 2010-05-27 University Of Exeter Agricultural treatment
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US9737561B2 (en) 2009-08-21 2017-08-22 Novan, Inc. Topical gels and methods of using the same
US10376538B2 (en) 2009-08-21 2019-08-13 Novan, Inc. Topical gels and methods of using the same
US11583608B2 (en) 2009-08-21 2023-02-21 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US9713652B2 (en) 2011-02-28 2017-07-25 The University Of North Carolina At Chapel Hill Nitric oxide-releasing S-nitrosothiol-modified silica particles and methods of making the same
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same
WO2020245574A1 (en) 2019-06-04 2020-12-10 Thirty Respiratory Limited Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
WO2020245573A1 (en) 2019-06-04 2020-12-10 Thirty Holdings Limited Methods and compositions for generating nitric oxide and uses thereof
WO2021214440A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2
WO2021214439A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Methods and compositions for treating and combatting tuberculosis
WO2022167797A1 (en) 2021-02-04 2022-08-11 Thirty Respiratory Limited Vaping e-liquid composition and use thereof

Also Published As

Publication number Publication date
JPH09508921A (en) 1997-09-09
FI963232A (en) 1996-09-12
BR9507099A (en) 1997-09-16
ATE264685T1 (en) 2004-05-15
CN1144484A (en) 1997-03-05
ES2218541T3 (en) 2004-11-16
FI114852B (en) 2005-01-14
NO963446L (en) 1996-10-21
PL180769B1 (en) 2001-04-30
AU1669995A (en) 1995-09-04
FI963232A0 (en) 1996-08-16
CA2183549A1 (en) 1995-08-24
EP0746327B1 (en) 2004-04-21
NO963446D0 (en) 1996-08-19
KR100385297B1 (en) 2003-10-10
CZ286286B6 (en) 2000-03-15
EP0746327A1 (en) 1996-12-11
DK0746327T3 (en) 2004-05-10
DE69532921T2 (en) 2005-04-14
CZ245696A3 (en) 1997-01-15
CA2183549C (en) 2006-09-12
NO311494B1 (en) 2001-12-03
DE69532921D1 (en) 2004-05-27
PL316033A1 (en) 1996-12-23
JP3875262B2 (en) 2007-01-31
CN1145491C (en) 2004-04-14
PT746327E (en) 2004-06-30
AU693851B2 (en) 1998-07-09

Similar Documents

Publication Publication Date Title
EP0746327B1 (en) Acidified nitrite as an antimicrobial agent
US6709681B2 (en) Acidified nitrite as an antimicrobial agent
Carlsson et al. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine
USRE37793E1 (en) Method and composition for inhibiting bacteria
RU2234945C2 (en) Stabilizing agent for aqueous solution and water-containing raw with spontaneously varying oxidative-reductive properties
US20060228384A1 (en) Control of biofilm with a biofilm inhibitor
US20100124537A1 (en) Medical applications of alpha-ketoglutarate
KR20150003908A (en) Applications of alpha-ketoglutarate for manufacturing organic biofuel
RU2104710C1 (en) Pharmaceutical bactericidal compositions and their using
WO2015022874A1 (en) Hydrogen-containing antimicrobial agent
JP4146146B2 (en) Antibacterial agent based on fluorotannins
CA2238484A1 (en) Antimicrobial composition and methods of use therefor
JPWO2010041400A1 (en) Biofilm formation inhibitor
CN111568919A (en) A preparation containing chitosan oligosaccharide for resisting helicobacter pylori
TWI277393B (en) Acidic solution of sparingly-soluble group IIA complexes
Yoshiyama et al. A novel in vitro effect of the mucosal protective agent sofalcone–inhibition of chemotactic motility in Helicobacter pylori
El-Kholany et al. Spectrophotometric and biological studies for the interaction of rifaximin with Co, Cu, Fe and vitamin C
CN112569225B (en) Non-drug helicobacter pylori bactericidal composition
Sukumaran et al. Can bio-nanotechnology be effective against multi drug resistant (MDR) pathogens?
Fette Pre-exposure of Escherichia coli and Staphylococcus aureus to sub-bactericidal concentrations of benzalkonium chloride and its effect on low-level antimicrobial resistance
L'Hirondel et al. The beneficial effects of nitrate.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95192199.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2183549

Country of ref document: CA

Ref document number: 963232

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1995908347

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV1996-2456

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 1996 696930

Country of ref document: US

Date of ref document: 19960821

Kind code of ref document: A

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995908347

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1996-2456

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1996-2456

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1995908347

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 963232

Country of ref document: FI